Supernus Pharmaceuticals Inc.

20 days ago · globenewswire.com

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:

22 days ago · globenewswire.com

ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.

29 days ago · zacks.com

Investors need to pay close attention to SUPN stock based on the movements in the options market lately.

29 days ago · defenseworld.net

Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) and Vectura Group (OTCMKTS:VEGPF - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership. Risk and Volatility Supernus Pharmaceuticals has a beta

1 month ago · defenseworld.net

Assenagon Asset Management S.A. lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 86.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,175 shares of the specialty pharmaceutical company's stock after selling 457,443 shares during the

2 months ago · zacks.com

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?

2 months ago · businesswire.com

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.

2 months ago · fool.com

The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.

2 months ago · seekingalpha.com

Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript

2 months ago · prnewswire.com

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) related to its sale to Indivior Pharmaceuticals, Inc. Under the terms of the proposed transaction, Supernus shareholders are expected to receive 1.5401 common shares of Indivior for each share of Supernus.